Your browser doesn't support javascript.
loading
The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study.
Ye, Chuchu; Zhang, Ge; Zhang, Anran; Xin, Hualei; Wu, Kang; Li, Zhongjie; Jia, Yilin; Hao, Lipeng; Xue, Caoyi; Wang, Yuanping; Xu, Hongmei; Zhu, Weiping; Zhou, Yixin.
Affiliation
  • Ye C; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Zhang G; School of Public Health, Dali University, Dali 671003, China.
  • Zhang A; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Xin H; World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Wu K; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Li Z; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100073, China.
  • Jia Y; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Hao L; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Xue C; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Wang Y; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Xu H; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Zhu W; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
  • Zhou Y; Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Vaccines (Basel) ; 11(7)2023 Jun 25.
Article in En | MEDLINE | ID: mdl-37514962
ABSTRACT
Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI] 11.6-14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI 9.2-13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI 12.3-18.1) (adjusted odds ratio [aOR] 0.579; 95% CI 0.412-0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Language: En Journal: Vaccines (Basel) Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Language: En Journal: Vaccines (Basel) Year: 2023 Document type: Article Affiliation country: China